EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients

Heather Weerdenburg iD, Hannah Walker, Gabrielle M Haeusler, Theresa Cole, Nigel Curtis, Stephen Duffull, Amanda Gwee

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae473 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Heather Weerdenburg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Cancer Centre, General Medicine and Allergy and Immunology, Royal Children's Hospital, Parkville, Australia. Hauptthemen laut MEDLINE: Triazoles, Hematopoietic Stem Cell Transplantation, Antifungal Agents, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posaconazole is used to prevent and treat invasive fungal infections (IFIs) in immunocompromised children, including those undergoing cancer treatment or HSCT. Despite differences in pharmacokinetics and IFI epidemiology between children and adults, therapeutic targets established in adult studies are often applied to children.

Objectives

This systematic review evaluated the correlation between serum posaconazole concentrations and clinical outcomes of IFI prophylaxis and treatment in children with malignancies or HSCT recipients.

Methods

Four databases (Cochrane, Embase, MEDLINE and PubMed) were searched for studies involving children (≤18 years old) receiving cancer treatment or HSCT that reported posaconazole serum concentrations and treatment outcomes. Animal studies, those primarily in adult (>18 years old) populations, non-malignant conditions (excluding HSCT), case reports, letters, editorials, conference abstracts and narrative reviews were excluded. Bias was assessed using the Newcastle–Ottawa scale.

Results

Nineteen studies were included: 12 reported outcomes of posaconazole prophylaxis; two of treatment; and five of both. For prophylaxis, breakthrough IFIs occurred in 1%–12% of children. All but one occurred with serum concentrations of ≤0.7 mg/L. For treatment, no clear association was observed between a trough concentration of >1.0 mg/L and treatment efficacy, with poor outcomes reported for serum concentrations ranging between 0.2 and 4.8 mg/L. Overall, quality of evidence was poor (medium to high risk of bias for 18 papers, low risk for 1 paper) and there was variation in IFI definitions across studies.

Conclusions

This review supports current recommendations for posaconazole prophylaxis in paediatric oncology and HSCT recipients. The absence of a clear correlation found between serum trough concentrations and treatment efficacy highlights the need for further studies to determine optimal therapeutic targets for treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesHematopoietic Stem Cell TransplantationAntifungal AgentsNeoplasmsInvasive Fungal InfectionsHumansChildTreatment OutcomeAdolescentImmunocompromised HostChild, PreschoolTransplant Recipients

Substanzen

posaconazoleTriazolesAntifungal Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Cancer Centre, General Medicine and Allergy and Immunology, Royal Children's Hospital, Parkville, Australia.
  • Antimicrobials, Clinical Paediatrics, and Infectious Diseases Groups, Murdoch Children's Research Institute, Parkville, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Australia.
  • Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Australia.
  • Sir Peter MacCallum Department of Oncology, NHMRC National Centre for Infections in Cancer, University of Melbourne, Melbourne, Australia.
  • The Victorian Paediatric Integrated Cancer Service, Victoria State Government, Melbourne, Australia.

ORCID-Profile: Heather Weerdenburg

Zitieren

APA

Weerdenburg, H., Walker, H., Haeusler, G. M., Cole, T., Curtis, N., Duffull, S., & Gwee, A. (2025). Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae473

Vancouver

Weerdenburg H, Walker H, Haeusler GM, Cole T, Curtis N, Duffull S, et al. Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae473

BibTeX
@article{Weerdenburg2025,
  author = {Weerdenburg, Heather and Walker, Hannah and Haeusler, Gabrielle M and Cole, Theresa and Curtis, Nigel and Duffull, Stephen and Gwee, Amanda},
  title = {Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae473}
}
Kostenlos starten →